Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 41,900 shares, a growth of 23.6% from the November 30th total of 33,900 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average trading volume of 14,000 shares, the short-interest ratio is currently 3.0 days.
NASDAQ PRE traded down $0.03 on Tuesday, reaching $5.80. 10,471 shares of the stock traded hands, compared to its average volume of 47,859. Prenetics Global has a 12 month low of $2.85 and a 12 month high of $7.84. The firm's fifty day simple moving average is $4.90 and its 200 day simple moving average is $5.11. The company has a market cap of $52.99 million, a price-to-earnings ratio of -1.45 and a beta of -0.18.
Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its quarterly earnings results on Monday, October 7th. The company reported ($0.88) EPS for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%. The business had revenue of $5.94 million during the quarter. As a group, equities research analysts forecast that Prenetics Global will post -3.3 EPS for the current fiscal year.
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $9.00 target price on shares of Prenetics Global in a research report on Wednesday, December 4th.
Check Out Our Latest Report on Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.